Leadership

Xiling Shen, PhD
Xiling Shen, PhD
Founder, Chief Executive Officer

Dr. Shen is co-founder and Chief Executive Officer of Xilis. He has 13 years of industrial and academic experience as a design engineer and faculty member at Cornell University and Duke University. His work focuses on combining engineering, computational and biological techniques to study patient models of cancer and precision medicine. Dr. Shen is currently the Hawkins Family Associate Professor in the Department of Biomedical Engineering at Duke, the Director of the Woo Center for Big Data and Precision Health (DAP) and a core member of the Center for Genomics and Computational Biology (GCB). He received his BS, MS, and PhD from Stanford University.

David Hsu, MD, PhD
David Hsu, MD, PhD
Founder, Chief Medical Officer

Dr. Hsu is co-founder and Chief Medical Officer of Xilis. He is a medical oncologist and is currently Associate Professor of Medicine at Duke University Medical Center. Dr. Hsu’s clinical interests include gastrointestinal malignancies and colorectal cancer. His lab focuses on using patient models of cancer, high-throughput genomic and proteomic technologies to develop new therapies and diagnostics for cancer. He received his MD and PhD from the University of North Carolina at Chapel Hill and completed his medical training at UT Southwestern Medical Center and Duke Medical Center.

Hans Clevers, MD, PhD
Hans Clevers, MD, PhD
Founder, Chief Scientist

Dr. Clevers is co-founder and Chief Scientist at Xilis, and the inventor of organoid technologies. He is the Principal Investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research (KNAW) and the Princess Máxima Center for Pediatric Oncology, Professor of Molecular Genetics at the UMC Utrecht and Utrecht University, and Oncode Investigator. Dr. Clevers was the first to identify living stem cells in the intestine and is one of the world's leading researchers on adult stem cells, their role in cancer and their potential for regenerative therapy. Dr. Clevers received his MD and PhD from the University of Utrecht.

Daniel Delubac, PhD
Daniel Delubac, PhD
Chief Operating Officer and VP, Platform

Dr. Delubac is Chief Operating Officer and VP, Platform at Xilis. He is a Silicon Valley veteran with 10 years of experience in developing transformative oncology platforms and an expert in laboratory efficiency and product development. Dr. Delubac was previously VP of Laboratory Technologies and Operations at Freenome. He also served as Head of Process Engineering/Lab Automation at Guardant health. Dr. Delubac received his PhD in Bioengineering and Biomedical Engineering from Carnegie Mellon University.

Gary Yeung
Gary Yeung
Chief Financial Officer and President of Biopharma

Gary Yeung is a life science executive (COO, CFO, and CBO), board member, and senior advisor with extensive strategy, finance, business development, and operations experience in forming and building biotech companies and developing novel therapies. He has raised over $500M ($300M as CFO and $200M as an advisor and board member).

Forming and building four successful biotech companies: Erasca, NiKang, Guardant Health, and Annexon Biosciences. Led organizations engaged in filing 42 INDs and launching multiple FDA-approved treatments at Genentech. Management consulting at McKinsey and operation leadership at GE.

Stan Skrzypczak, MS, MBA
Stan Skrzypczak, MS, MBA
Chief Business Officer (Acting)

Mr. Skrzypczak is Acting Chief Business Officer of Xilis and has more than 30 years of experience working in corporate and business development as well as leading startups towards a global footprint while increasing shareholder value or building toward an IPO. He was previously VP, Corporate Development and Reimbursement at Guardant Health and VP, Business Development at Invitae. Mr. Skrzypczak also held senior commercial roles at Genomic Health and Genentech. He received his BA in Biochemistry from the University of Rochester, MS in Microbiology and Immunology from Wright State University, and MBA from Xavier University.